Relationship of different platelet response criteria and patient outcomes in a romiplostim myelodysplastic syndromes trial

U. Platzbecker; M. A. Sekeres; H. Kantarjian; A. Giagounidis; G. J. Mufti; C. Jia; A. S. Yang; P. Fenaux

doi:10.1038/leu.2014.253

Relationship of different platelet response criteria and patient outcomes in a romiplostim myelodysplastic syndromes trial

U. Platzbecker, M. A. Sekeres, H. Kantarjian, A. Giagounidis, G. J. Mufti, C. Jia, A. S. Yang, P. Fenaux

Leukemia

Research output: Contribution to journal › Letter › peer-review

10 Scopus citations

Original language	English (US)
Pages (from-to)	2418-2421
Number of pages	4
Journal	Leukemia
Volume	28
Issue number	12
DOIs	https://doi.org/10.1038/leu.2014.253
State	Published - Dec 11 2014

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1038/leu.2014.253

Cite this

@article{9732a3b664f84dd898fd79dc757a5219,

title = "Relationship of different platelet response criteria and patient outcomes in a romiplostim myelodysplastic syndromes trial",

author = "U. Platzbecker and Sekeres, {M. A.} and H. Kantarjian and A. Giagounidis and Mufti, {G. J.} and C. Jia and Yang, {A. S.} and P. Fenaux",

note = "Funding Information: Medical writing assistance was provided by Susanna Mac of Amgen. Funding for these analyses was provided by Amgen. Funding Information: UP has received honoraria from Amgen, GlaxoSmithKline (GSK), Celgene and Novartis. MAS is a member of advisory boards for Amgen and Celgene, and a speaker for Celgene. HK has research grants from Amgen. AG is a member of advisory boards and a speaker for Amgen and GSK. GJM has been a member of advisory boards and speakers bureau for Amgen, Novartis, GSK and Celgene, received research funding from Celgene and has been a consultant for GSK. CJ and ASY are employees of and stockholders in Amgen. PF has received honoraria and research grants from Amgen, Celgene, Janssen Roche, GSK and Novartis. Funding Information: This work was supported by NIH/NCI grant CA134458 to T Skorski.",

year = "2014",

month = dec,

day = "11",

doi = "10.1038/leu.2014.253",

language = "English (US)",

volume = "28",

pages = "2418--2421",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Nature Publishing Group",

number = "12",

}

TY - JOUR

T1 - Relationship of different platelet response criteria and patient outcomes in a romiplostim myelodysplastic syndromes trial

AU - Platzbecker, U.

AU - Sekeres, M. A.

AU - Kantarjian, H.

AU - Giagounidis, A.

AU - Mufti, G. J.

AU - Jia, C.

AU - Yang, A. S.

AU - Fenaux, P.

N1 - Funding Information: Medical writing assistance was provided by Susanna Mac of Amgen. Funding for these analyses was provided by Amgen. Funding Information: UP has received honoraria from Amgen, GlaxoSmithKline (GSK), Celgene and Novartis. MAS is a member of advisory boards for Amgen and Celgene, and a speaker for Celgene. HK has research grants from Amgen. AG is a member of advisory boards and a speaker for Amgen and GSK. GJM has been a member of advisory boards and speakers bureau for Amgen, Novartis, GSK and Celgene, received research funding from Celgene and has been a consultant for GSK. CJ and ASY are employees of and stockholders in Amgen. PF has received honoraria and research grants from Amgen, Celgene, Janssen Roche, GSK and Novartis. Funding Information: This work was supported by NIH/NCI grant CA134458 to T Skorski.

PY - 2014/12/11

Y1 - 2014/12/11

UR - http://www.scopus.com/inward/record.url?scp=84927084484&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927084484&partnerID=8YFLogxK

U2 - 10.1038/leu.2014.253

DO - 10.1038/leu.2014.253

M3 - Letter

C2 - 25179731

AN - SCOPUS:84927084484

SN - 0887-6924

VL - 28

SP - 2418

EP - 2421

JO - Leukemia

JF - Leukemia

IS - 12

ER -

Relationship of different platelet response criteria and patient outcomes in a romiplostim myelodysplastic syndromes trial

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this